Pricing Availability   Qty
Description: COMT inhibitor
Chemical Name: 5-[3-(2,5-Dichloro-4,6-dimethyl-1-oxido-3-pyridinyl)-1,2,4-oxadiazol-5-yl]-3-nitro-1,2-benzenediol
Purity: ≥98% (HPLC)
Literature (1)

Biological Activity for Opicapone

Opicapone is a reversible catechol O-methyltransferase inhibitor (COMT) inhibitor (IC50 = 224 nM). Decreases the ATP content and mitochondrial membrane potential in cells (IC50 values are 98 μM and 181 μM respectively). When administered with L-DOPA (Cat. No. 3788) it attenuates Parkinson's-like symptoms in an MPTP-induced animal model.

Technical Data for Opicapone

M. Wt 413.17
Formula C15H10Cl2N4O6
Storage Store at -20°C
Purity ≥98% (HPLC)
CAS Number 923287-50-7
PubChem ID 135565903
Smiles OC1=CC(C2=NC(C3=C(C(Cl)=C([N+]([O-])=C3Cl)C)C)=NO2)=CC([N+]([O-])=O)=C1O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for Opicapone

Solvent Max Conc. mg/mL Max Conc. mM
DMSO 41.32 100

Preparing Stock Solutions for Opicapone

The following data is based on the product molecular weight 413.17. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.42 mL 12.1 mL 24.2 mL
5 mM 0.48 mL 2.42 mL 4.84 mL
10 mM 0.24 mL 1.21 mL 2.42 mL
50 mM 0.05 mL 0.24 mL 0.48 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

References for Opicapone

References are publications that support the biological activity of the product.

Ettcheto et al (2020) The preclinical discovery and development of opicapone for the treatment of Parkinson's disease. Expert Opin.Drug Discov. 15 993 PMID: 32450711

Bonifácio et al (2021) Opicapone enhances the reversal of MPTP-induced Parkinson-like syndrome by levodopa in cynomolgus monkeys. Eur.J.Pharmacol. 892 173742 PMID: 33220276

If you know of a relevant reference for Opicapone, please let us know.

View Related Products by Target

View Related Products by Product Action

View all Catechol O-Methyltransferase Inhibitors

Keywords: Opicapone, Opicapone supplier, comt, inhibitors, catechol-O-methytransferases, mitochondrial, membrane, potential, ATP, LDOPA, levodopa, Parkinsons, Catechol, O-Methyltransferase, 7668, Tocris Bioscience

Citations for Opicapone

Citations are publications that use Tocris products.

Currently there are no citations for Opicapone. Do you know of a great paper that uses Opicapone from Tocris? Please let us know.

Reviews for Opicapone

There are currently no reviews for this product. Be the first to review Opicapone and earn rewards!

Have you used Opicapone?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.